- Home
- ETJ vs IMTX Comparison
ETJ vs IMTX Comparison
Compare ETJ & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETJ
- IMTX
- Stock Information
- Founded
- ETJ 2007
- IMTX N/A
- Country
- ETJ United States
- IMTX Germany
- Employees
- ETJ N/A
- IMTX N/A
- Industry
- ETJ Finance Companies
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETJ Finance
- IMTX Health Care
- Exchange
- ETJ Nasdaq
- IMTX Nasdaq
- Market Cap
- ETJ 578.8M
- IMTX 514.2M
- IPO Year
- ETJ N/A
- IMTX N/A
- Fundamental
- Price
- ETJ $8.17
- IMTX $4.26
- Analyst Decision
- ETJ
- IMTX Strong Buy
- Analyst Count
- ETJ 0
- IMTX 4
- Target Price
- ETJ N/A
- IMTX $16.67
- AVG Volume (30 Days)
- ETJ 175.6K
- IMTX 849.5K
- Earning Date
- ETJ 01-01-0001
- IMTX 05-13-2025
- Dividend Yield
- ETJ 8.30%
- IMTX N/A
- EPS Growth
- ETJ N/A
- IMTX N/A
- EPS
- ETJ N/A
- IMTX 0.14
- Revenue
- ETJ N/A
- IMTX $161,336,577.00
- Revenue This Year
- ETJ N/A
- IMTX N/A
- Revenue Next Year
- ETJ N/A
- IMTX $18.80
- P/E Ratio
- ETJ N/A
- IMTX $29.39
- Revenue Growth
- ETJ N/A
- IMTX 188.60
- 52 Week Low
- ETJ $7.20
- IMTX $3.30
- 52 Week High
- ETJ $8.47
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- ETJ 43.06
- IMTX 48.54
- Support Level
- ETJ $7.40
- IMTX $4.03
- Resistance Level
- ETJ $8.87
- IMTX $4.48
- Average True Range (ATR)
- ETJ 0.33
- IMTX 0.39
- MACD
- ETJ -0.00
- IMTX 0.05
- Stochastic Oscillator
- ETJ 52.38
- IMTX 75.00
About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.